Katie Shi is an experienced analyst currently at Guidepoint, where responsibilities include covering over 80 SMID cap biotech stocks and conducting live interviews with key opinion leaders on clinical trial data and treatment trends, with a focus on immuno-oncology, cell therapies, and rare diseases. Previous roles include Associate Research Scientist positions at Cellectis and Pfizer, where Katie developed mRNA arms for gene editing tools and supported high-throughput protein production for biotherapeutic design, respectively. Katie began her academic journey at Skidmore College, earning a Bachelor’s degree in Biochemistry while engaging in multiple research projects and leadership roles, including serving as President of the Chemistry Club and assisting laboratory courses.
This person is not in the org chart
This person is not in any teams
This person is not in any offices